Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 1/2006

01-01-2006 | Original Article

Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type

Authors: Chiara Pratesi, Maria Teresa Bortolin, Ettore Bidoli, Rosamaria Tedeschi, Emanuela Vaccher, Riccardo Dolcetti, Massimo Guidoboni, Gianni Franchin, Luigi Barzan, Stefania Zanussi, Calogero Caruso, Paolo De Paoli

Published in: Cancer Immunology, Immunotherapy | Issue 1/2006

Login to get access

Abstract

Purpose: Cytokines such as IL-10 and IL-18 seem to be involved in the inflammatory response of undifferentiated carcinoma of nasopharyngeal type (UCNT). The aim of this study was to evaluate the correlation between functional single nucleotide polymorphisms (SNPs) in the promoter region of IL-10 and IL-18 genes and the virological and clinical characteristics in a large case series of Caucasian patients suffering from UCNT, a tumor regularly associated with the Epstein Barr Virus (EBV). Methods: Eighty-nine patients with histologically confirmed UCNT and 130 healthy donors were included in our study. DNA was examined for the polymorphisms of IL-10 gene at positions –1082, −819, −592 by direct sequencing and IL-18 gene at position −607 and −137 by allele –specific PCR. EBV DNA serum viremia was evaluated by QC-PCR. Results: The distributions of the IL-10 and IL-18 genetic variants were not different between UCNT patients and healthy controls. The frequency of IL-10 –1082G allele, which is associated with high IL-10 expression, showed a nearly statistically significant increase in UCNT patients EBV DNA-negative as compared to healthy controls (OR=3.3 95% CI: 1.2–9.8). Subjects with C/C or C/G combined IL-18 genotypes showed an increased risk of being with Stages III-IV (OR=2.1 95% CI: 1.2–6.6). Conclusion: This study was performed to improve the definition of the pathogenetic factors implicated in UCNT by addressing the correlation between cytokine polymorphisms and clinical parameters. This is the first study investigating the possible role of the IL-18 and IL-10 polymorphisms in the development and outcome of UCNT. In our genetic analysis there is no evidence for involvement of IL-10 promoter polymorphisms alone in the genetic predisposition to this tumor. On the other hand, IL18 genetic variants may represent a genetic risk factor for tumor aggressiveness.
Literature
1.
Agarwal P, Oldenburg MC, Czarneski JE, Morse RM, Hameed MR, Cohen S, Fernandes H (2000) Comparison study for identifying promoter allelic polymorphism in interleukin 10 and tumor necrosis factor alpha genes. Diagn Mol Pathol 9:158–164CrossRefPubMed
2.
Baumforth KR, Young LS, Flavell KJ, Constantinidou C, Murray PG (1999) The Epstein-Barr virus and its association with human cancers. Mol Pathol 52:307–322PubMedCrossRef
3.
Behars OH, Henson DE, Hutter RVP, Kennedy BJ (1992) Pharynx 33–8. In: manual for staging of cancer. JB Lippincott, Philadelphia
4.
Blackwell JM (2001) Genetics and genomics in infectious disease susceptibility. Trends Mol Med 7:521–526CrossRefPubMed
5.
Breslow NE, Day NE (1980) Statistical methods in cancer research, vol I. The analysis of case-control studies. IARC Sci Publ 32:335–338
6.
Budiani DR, Hutahaean S, Haryana SM, Soesatyo MH, Sosroseno W (2002) Interleukin-10 levels in Epstein-Barr virus-associated nasopharyngeal carcinoma. J Microbiol Immunol Infect 35:265–268PubMed
7.
Cardoso SM, DeFor TE, Tilley LA, Bidwell JL, Weisdorf DJ, MacMillan ML (2004) Patient interleukin-18 GCG haplotype associates with improved survival and decreased transplant-related mortality after unrelated-donor bone marrow transplantation. Br J Haematol 126:704–710CrossRefPubMed
8.
Chan KC, Zhang J, Chan AT, Lei KI, Leung SF, Chan LY, Chow KC, Lo YM (2003) Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 63:2028–2032PubMed
9.
Comar M, Simonelli C, Zanussi S, De Paoli P, Vaccher E, Tirelli U, Giacca M (1997) Dynamics of HIV-1 mRNA expression in patients with long-term nonprogressive HIV-1 infection. J Clin Invest 100:893–903PubMedCrossRef
10.
Cooke GS, Hill AV (2001) Genetics of susceptibility to human infectious diseases. Nat Rev Genet 2:967–977CrossRefPubMed
11.
Crawford DH (2001) Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 356:461–473PubMedCrossRef
12.
Eskdale J, Kube D, Gallagher G (1996) A second polymorphic dinucleotide repeat in the 5′ flanking region of the human IL10 gene. Immunogenetics 45:82–83CrossRefPubMed
13.
Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW (1998) Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A 95:9465–9470CrossRefPubMed
14.
Fliss-Jaber L, Houissa-Kastally R, Bouzouita K, Khediri N, Khelifa R (2004) Cytokine and immunoglobulin production by PWM-stimulated peripheral and tumor-infiltrating lymphocytes of undifferentiated nasopharyngeal carcinoma (NPC) patients. BMC Cancer 4(1):68–77PubMedCrossRef
15.
Fujieda S, Lee K, Sunaga H, Tsuzuki H, Ikawa H, Fan GK, Imanaka M, Takenaka H, Saito H (1999) Staining of interleukin-10 predicts clinical outcome in patients with nasopharyngeal carcinoma. Cancer 85:1439–1445CrossRefPubMed
16.
Giedraitis V, He B, Huang WX, Hillert J (2001) Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol 112:146–152CrossRefPubMed
17.
Haanpaa M, Nurmikko T, Hurme M (2002) Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster. Scand J Infect Dis 34:112–114CrossRefPubMed
18.
Helminen M, Kilpinen S, Virta M, Hurme M (2001) Susceptibility to primary EBV infection is associated with IL-10 gene promoter polymorphism. J Infect Dis 184:777–780CrossRefPubMed
19.
Herrmann K, Niedobitek G (2003) Epstein-Barr virus- associated carcinomas: facts and fiction. J Pathol 199:140–145CrossRefPubMed
20.
Hohler T, Kruger A, Gerken G (1998) A TNF-alpha promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 11:579–582CrossRef
21.
Howell WM, Turner SJ, Bateman AC, Theaker JM (2001) IL-10 promoter polymorphisms influence tumor development in cutaneous malignant melanoma. Genes Immun 2:25–31CrossRefPubMed
22.
Hu H, Tang KF, Chua YN, Lu J, Feng P, Chew CT, Chan SH (2004) Expression of interleukin-18 by nasopharyngeal carcinoma cells: a factor that possibly initiates the massive leukocyte infiltration. Hum Pathol 35:722–728CrossRefPubMed
23.
Hurme M, Lahdenpohja N, Santtila S (1998) Gene polymorphisms of interleukins 1 and 10 in infectious and autoimmune diseases. Ann Med 30:469–73PubMed
24.
Janssen R, Grutters JC, Ruven HJ, Zanen P, Sato H, Welsh KI, du Bois RM, van den Bosch JM (2004) No association between interleukin-18 gene polymorphisms and haplotypes in Dutch sarcoidosis patients. Tissue Antigens 63:578–583CrossRefPubMed
25.
Karhukorpi J, Karttunen R (2001) Genotyping interleukin-10 high and low producers with single-tube bidirectional allele-specific amplification. Exp Clin Immunogenet 18:67–70CrossRefPubMed
26.
Lio D, Scola L, Crivello A, Colonna-Romano G, Candore G, Bonafe M, Cavallone L, Franceschi C, Caruso C (2002) Gender-specific association between −1082 IL-10 promoter polymorphism and longevity. Genes Immun 3:30–33CrossRefPubMed
27.
Lo YM, Chan LY, Chan A, Leung S, Lo K, Zhang J, Lee J, Hjelm M, Johnson P, Huang D (1999) Quantitative and temporal correlation between circulating cell-free EBV-DNA and tumor recurrence in nasopharingeal carcinoma. Cancer Res 59:5452–5455PubMed
28.
Muti G, Klersy C, Baldanti F, Granata S, Oreste P, Pezzetti L, Gatti M, Gargantini L, Caramella M, Mancini V, Gerna G, Morra E (2003) EBV load and IL-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. Br J Haematol 122:927–33CrossRefPubMed
29.
Mutirangura A, Pornthanakasem W, Theamboonlers A, Sriuranpong V, Lertsanguanisinchi P, Yenrudi S, Voravud N, Suphyabun P, Poovorawan Y (1998) Epstein-Barr viral DNA in serum of patients with nasopharingeal carcinoma. Clin Cancer Res 4:665–669PubMed
30.
Poli F, Nocco A, Berra S, Scalamogna M, Taioli E, Longhi E, Sirchia G (2002) Allele frequencies of polymorphisms of TNFA, IL-6, IL-10 and IFNG in an Italian Caucasian population. Eur J Immunogenet 29:237–240CrossRefPubMed
31.
Pratesi C, Bortolin MT, D’Andrea M, Vaccher E, Barzan L, Bidoli E, Tedeschi R, Zanussi S, De Paoli P (2003) Quantitative plasma/serum EBV DNA load by LMP2a determination in an Italian cohort of NPC patients. J Clin Virol 28:155–164CrossRefPubMed
32.
Scola L, Crivello A, Marino V, Gioia V, Serauto A, Candore G, Colonna-Romano G, Caruso C, Lio D (2003) IL-10 and TNF-alpha polymorphisms in a sample of Sicilian patients affected by tuberculosis: implication for ageing and life span expectancy. Mech Ageing Dev 124:569–572CrossRefPubMed
33.
Shanmugaratnam K, Sobin LH (1991) Histological typing of tumors of the upper respiratory tract and ear. World Health Organization: international histological classification of tumors. Springer Berlin Heidelberg New York
34.
Stassen NA, Breit CM, Norfleet LA, Polk HC Jr (2003) IL-18 promoter polymorphisms correlate with the development of post-injury sepsis. Surgery 134:351–356CrossRefPubMed
35.
Terwilliger JD, Ott J (1994) Linkage disequilibrium between alleles at marker loci 188–193. In: Handbook of human genetics linkage. The John Hopkins University Press, Baltimore
36.
Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1–8PubMed
37.
Uboldi de Capei MU, Dametto E, Fasano ME, Rendine S, Curtoni ES (2003) Genotyping for cytokine polymorphisms: allele frequencies in the Italian population. Eur J Immunogenet 30:5–10CrossRefPubMed
38.
39.
Wu M, Huang S, Shun T, Chang M, Lin M., Wang P, Lin J (2002) TNF-α and IL-10 promoter polymorphisms in EBV-associated gastric carcinoma. J Infect Dis 185:106–109CrossRefPubMed
40.
Yao M, Ohshima K, Suzumiya J, Kume T, Shiroshita T, Kikuchi M (1997) Interleukin-10 expression and cytotoxic-T-cell response in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer 72:398–402CrossRefPubMed
41.
Zanussi S, Vaccher E, Caffau C, Pratesi C, Crepaldi C, Bortolin MT, Tedeschi R, Politi D, Barzan L, Tirelli U, De Paoli P (2003) Interferon-γ secretion and perforin expression are impaired in CD8+ lymphocytes from patients with UCNT. Cancer Immunol Immunother 52:28–32PubMed
Metadata
Title
Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type
Authors
Chiara Pratesi
Maria Teresa Bortolin
Ettore Bidoli
Rosamaria Tedeschi
Emanuela Vaccher
Riccardo Dolcetti
Massimo Guidoboni
Gianni Franchin
Luigi Barzan
Stefania Zanussi
Calogero Caruso
Paolo De Paoli
Publication date
01-01-2006
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 1/2006
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-005-0688-z

Other articles of this Issue 1/2006

Cancer Immunology, Immunotherapy 1/2006 Go to the issue

Original Article

Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin

Symposium Paper

Immunogenic HER-2/neu peptides as tumor vaccines

Symposium Paper

Characterization of glycosylation and adherent properties of melanoma cell lines

Symposium Paper

Adoptive T cell therapy of solid cancers

Review

Mouse models of efficient and inefficient anti-tumor immunity, with emphasis on minimal residual disease and tumor escape

Original Article

Tripeptide tyroserleutide enhances the antitumor effects of macrophages and stimulates macrophage secretion of IL-1β, TNF-α, and NO in vitro
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits